Herzeliya · Pre-Seed–Late Stage · 9 people tracked
Find your way into Pontifax Venture Capital
1,014 people in our graph share verified history with the Pontifax Venture Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Pontifax invests globally in groundbreaking life sciences and healthcare innovation. Its approach spans the full company lifecycle: an entrepreneurship focus scouting disruptive ideas within research centers and building companies from the ground up; early-stage investing with hands-on guidance, networking and operational experience to boost the odds of success; and growth-stage investing in clinical-stage companies where the firm offers strategic direction plus capital markets and M&A expertise. The firm seeks transformative healthcare technologies at every stage of development and sources opportunities worldwide.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website & curated
Founder mafia
2 people who came through Pontifax Venture Capital went on to found or lead other companies.
What they invest in
from 53 of 70 portfolio companiesBiotech ×43Healthtech ×35Medical Devices ×22AI & Machine Learning ×8Deep Tech ×4Digital Health ×4Longevity ×4Hardware ×3
HQs:United States×25Israel×8Belgium×2Switzerland×1Denmark×1France×1
Who they back
founder profiles across 20 portfolio companiesFounding team size:solo founder×132 founders×53 founders×2
Investments · showing 66 of 70
founders shown can be your intro pathBy year:2024 · 32023 · 22022 · 12021 · 42020 · 12017 · 22014 · 114 dated
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)Heather Turner(President & Chief Executive Officer and Director)Gad Soffer(Chief Operating and Business Officer)Anna Eramo(Chief Medical Officer)
Board seatRan Nussbaum· per SEC Form D
Co-investorsTarnagulla VenturesVida VenturesTCG Crossover
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)
BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)
Co-investorsForesite CapitalOrbiMedQuan CapitalaMoonNovartis Venture FundPureTech Health
Check-Cap is a clinical-stage medical diagnostics company that developed the C-Scan System, an ingestible capsule for colorectal cancer screening that requires no bowel preparation or sedation.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesRoboticsIsfiya, IL
Lior Torem(Executive Officer)Yoav Kimchy(Executive Officer)Yuval Yanai(Director)Alex Ovadia(Executive Officer)Walter Robb(Director)William Densel.(Executive Officer, Director)
Co-investorsProsper Startup Accelerator
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
Andreas Muehler(Executive Officer)inDaniel Vitt(Executive Officer, Director)inINDERPAL SINGH(Executive Officer)inHella Kohlhof(Executive Officer)Patrick Walsh(Executive Officer)Aron Stern(Executive Officer)
Co-investorsBayern Kapitalbmp VenturesFund+Omega Funds
Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.
BiotechHealthtechLexington, US
Jasbir S. Seehra(Executive Officer, Director)inJasbir Seehra(Co-Founder, Chief Executive Officer and Director)in
BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in
Co-investorsArkin CapitalForesite CapitalOrbiMed
Mereo BioPharma is a biopharmaceutical company publicly traded on Nasdaq under the ticker MREO.
BiotechHealthtechLondon, GB
John Richard(Head of Corporate Development and Co-Founder)inCharles Sermon(General Counsel and Co-Founder)Richard Jones(Chief Financial Officer)inJill Henrich(Senior Vice President)inDenise Scots-Knight(Chief Executive Officer)in
BoardDr. Deepa Pakianathan(Non-Executive Director)
Co-investorsVivo CapitalWoodford Investment Management
Protalix is a biopharmaceutical company that develops and manufactures innovative pharmaceutical products, including treatments for orphan and rare diseases.
BiotechHealthtechMedical DevicesKarmiel, IL
Moshe Bashan(President and Chief Executive Officer)Dror Bashan(President and Chief Executive Officer, Director)in
Co-investorsSofinnova Ventures
Soligenix is a biopharmaceutical company developing treatments for rare diseases, with programs in photodynamic therapy for cutaneous T-cell lymphoma and psoriasis, immunomodulatory drugs for inflammatory conditions, and vaccine candidates for infectious diseases.
BiotechPrinceton, US
Richard C. Straube, MD MSc(Executive Officer)Karen Krumeich(Executive Officer)Oreola Donini, PhD(Executive Officer)Christopher J. Schaber, PhD(Executive Officer, Director)inChristopher J. Schaber(Chairman of the Board, Chief Executive Officer and President)Adam T. Rumage(Executive Officer)
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatTomer Kariv· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more
UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology.
BiotechHealthtechMedical DevicesPrinceton, US
Mark Schoenberg, M.D.(Executive Officer)Liz Barrett(President and Chief Executive Officer)inJason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Don Kim(Executive Officer)
.jpg)
Board seatRan Nussbaum· per SEC Form D
Co-investorsAisling CapitalMonograph Capital Partners
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsVida VenturesHealthCapJeito CapitalNovo HoldingsOrbiMedRA Capital+2 more
Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.
BiotechHealthtechMedical Devices
Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in
Co-investorsaMoonRA CapitalBpifranceAndera PartnersAngelini VenturesKurma Partners+1 more
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.
BiotechHealthtechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)in
Co-investorsEQT Life SciencesAdBio partnersAndera PartnersAsabys PartnersCanaan PartnersV-Bio Ventures+1 more
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.
BiotechBasel, CH
Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in
Co-investorsNovartis Venture FundPfizer Venture Investments
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalAmzak HealthDelos CapitalDomain Associates+8 more
CathWorks develops the FFRangio System, a medical device that uses artificial intelligence and imaging technology to improve the diagnosis and treatment of coronary artery disease for interventional cardiologists and cardiac patients.
AI & Machine LearningDigital HealthMedical Devices
Ran Kornowski, MD, FESC(Co-Founder)Guy Lavi(Co-Founder)Ifat Lavi, PhD(Co-Founder)
Co-investorsPlanven Entrepreneur VenturesTriventures
This site publishes articles about regulatory affairs for immunotherapy, covering topics such as EMA approval processes, orphan drug designation, biomarkers, clinical trials, and compliance in manufacturing.
Biotech
CytoReason builds a computational disease model that maps disease and drug mechanisms by modeling and comparing treatments and patient groups.
AI & Machine LearningBiotechHealthtech
Co-investorsAsymmetry Ventures
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing small molecule therapeutics designed to address nonsense mutation genetic disorders.
BiotechHealthtechLongevityMedical Devices
Sumit Aggarwal(President and Chief Executive Officer)in
EyeYon Medical develops medical devices for corneal diseases, including EndoArt®, a synthetic implant for chronic corneal edema, and HyperCL™, a therapeutic contact lens for enhancing drug absorption in corneal conditions.
HardwareHealthtechMedical DevicesTel-Aviv, IL
Nahum Ferera(CEO, Co-founder)inDr. Ofer Daphna(Chief Medical Officer, Co-founder)Prof. Arie Marcovich(Co-founder)
Co-investorsTriventures
HealthtechParis
Ronald Buggage(Executive Officer)Thierry Bordet(Executive Officer)Francine Behar Cohen(Executive Officer, Promoter)Patricia Zilliox(Executive Officer, Director, Promoter)
Co-investorsKarista
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsLG Technology VenturesNovartis Venture FundOrbiMedSR One Capital ManagementWindham Capital PartnersMedicxi+1 more
Graviton offers an AI model trained on blockchain technology, including Solidity, to help developers build Web3 decentralized applications (dApps) from a prompt.
AI & Machine LearningCrypto & Web3Developer Tools
Co-investorsBlueYard Capital
Graviton develops immunomodulatory therapies for patients with fibrotic, autoimmune, and central nervous system diseases.
AI & Machine LearningBiotechDeep TechHealthtech
Samuel Waksal(Founder & CEO)
Imel Biotherapeutics is a biotech company focused on mitochondrial biology, targeting mitochondrial dysfunction implicated in aging, cellular senescence, and T cell exhaustion in the elderly population.
BiotechLongevity
Co-investorsRDiscovery
Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells.
BiotechHealthtechSanta Monica, US
Arie S. Belldegrun(Executive Officer, Director)inMargo R. Roberts(Executive Officer)Cynthia Butitta(Executive Officer)inMarc Better(Executive Officer)inRizwana Sproule(Executive Officer)in
BoardJoshua A. Kazam(Director)
Co-investorsAlta Partners
LogicBio is a biotechnology company focused on research and development of treatments for rare diseases, investigating new targets, modalities, and technologies for patients and their families worldwide.
BiotechHealthtechCambridge, US
Leszek Lisowski(Executive Officer, Director)Mark A. Kay(Director)Adi Barzel(Executive Officer, Director)
BoardErez Chimovits(Director)in
Co-investorsAndera PartnersArix BioscienceOrbiMed
Lutris Pharma develops targeted skin protection treatments for cancer patients, combining clinicians and scientists with oncology expertise.
BiotechDigital HealthHealthtechMedical Devices
Antoni Ribas, M.D., Ph.D.(Founder and Chairman of the Board)Sumant Ramachandra(Chief Executive Officer and Board Director)inJonathan Benjamin(Clinical Development Lead)
Co-investorsaMoonPeregrine Ventures
Nuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma.
BiotechHealthtechFort Lee, US
James Oliviero(Director)Enrique Poradosu(Executive Officer)Matthew Kaplan(Director)Michael Carson(Executive Officer)Kenneth Hoberman(Director)Ron Bentsur(Executive Officer, Director)
OCON Medical develops intrauterine devices for gynecological conditions, including non-hormonal contraception and treatments for abnormal uterine bleeding.
BiotechFemTechHealthtechMedical Devices
Ilan Baram(MD, Inventor of the IUB®)Keren Leshem(Chief Executive Officer)in
Co-investorsAstiaForeground Capital
Oxurion is a French specialist in clinical biometrics and data management, providing the core technology for the Oxurion platform.
AI & Machine LearningBiotechData & InfrastructureHealthtechMedical DevicesBrussels, BE
Co-investorsNegma Group
ProQR develops medicines for patients with unmet medical needs, focusing on therapeutic development in biotech.
BiotechHealthtechMedical DevicesLeiden, NL
Co-investorsInvivo Capital PartnersSofinnova Partners
Raziel develops a proprietary fat-dissolving injectable compound (RZL-012) for non-surgical, one-time focal fat reduction addressing both aesthetic and therapeutic needs, including submental (double-chin) fat and Dercum's disease.
BiotechHealthtechMedical DevicesHod Hasharon, IL
Alon Bloomenfeld(CEO & Founder)
Co-investorsPeregrine Ventures
Lifeward (ReWalk) develops wearable exoskeletons and related products for physical rehabilitation and recovery, used in conditions such as spinal cord injury, brain injury, stroke, multiple sclerosis, and orthopedic/sports medicine.
HealthtechMedical DevicesRobotics
Co-investorsSCP Vitalife Partners
RyCarma Therapeutics develops a novel drug class called Rycals to treat orphan skeletal muscle and cardiac diseases, building on foundational cardiovascular research and drug-delivery technologies.
BiotechHealthtechMedical DevicesNew York, US
Andrew R. Marks(Founding Scientist, MD)
Co-investorsKurma Partners
Saniona is a biotech company developing pharmacological therapies targeting dysfunctions in the brain, with a focus on CNS drug development and clinical advancement programs.
BiotechHealthtechMedical DevicesCopenhagen, DK
Thomas Feldthus(Co-founder and CEO)Janus Schreiber Larsen(Chief Operational Officer)Karin Sandager Nielsen(Chief Scientific Officer)
BiotechDigital HealthMedical DevicesSeattle, US
Peter A. Thompson(Executive Officer, Director)in
Co-investorsEcoR1 CapitalRA CapitalUS Venture Partners
Step Pharma develops oral cancer drugs that inhibit the enzyme cytidine triphosphate synthase 1 (CTPS1), with its lead therapeutic dencatistat in clinical development for lymphoma, solid tumors, and essential thrombocythaemia.
BiotechDeep TechMedical DevicesSaint-Genis-Pouilly, FR
Alain Fischer(Founding Scientist)
Co-investorsHadean VenturesKurma PartnersBpifranceSunstone CapitalV-Bio Ventures
StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases.
BiotechHealthtechDurham, US
Aravind Asokan(Director)inMavis Abjandje-McKenna(Director)Richard Smith(Executive Officer)inPatrick Ritschel(Executive Officer, Director, Promoter)
Co-investorsHatteras Venture Partners
Sweetch provides AI-driven personalized behavioral interventions that help patients manage chronic conditions through continuous engagement and adaptive recommendations.
AI & Machine LearningDigital HealthHealthtech
Co-investorsEntrée CapitalLionBirdTal VenturesTenmileOurCrowd
Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.
Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US
Ian Laffey(Founder)inSacha Lévy(Founder)in
Co-investorsY CombinatorAntlerFirst Round CapitalForesite CapitalLongitude CapitalLux Capital+4 more
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)inCarl Gordon(Director)in
Co-investorsForesite CapitalLongitude CapitalNextech InvestNexTech VenturesOrbiMedRock Springs Capital+1 more
V-Wave Medical develops a percutaneous implantable shunt device for treating chronic heart failure patients.
BiotechHealthtechMedical DevicesIsrael, IL
Co-investorsAPERTURE Venture PartnersBRM CapitalTriventures
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Jim Sullivan(CEO)inKevin Hunt(CSO)in
Co-investorsAvoro Capital AdvisorsOrbiMed
Vascular Graft Solutions develops medical device technologies for coronary revascularization procedures, with a focus on addressing vein graft disease in cardiac bypass surgery.
HardwareHealthtechMedical Devices
Eyal Orion(Founder & Active Chairman)in
Co-investorsBroadview VenturesGEOCTal Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Graviton Bioscience CorporationImel BioTherapeuticsAllena PharmaceuticalsAllenapharmaArquleDynacureEmergence TherapeuticsEmergencetxForSight VISION6 IncKamari PharmaMetabomedOpiantPactpharmaPRECIRIX NVPrevailtherapeuticsStargazer PharmaceuticalsTargedysV-WaveVanqua BioVbiv
Exits · 10
9 IPOs · 1 acquisitionsLB PharmaceuticalsNASDAQ: LBRXAdicet BioNASDAQ: ACETCheck CapNASDAQ: MBAIEnlivexNASDAQ: ENLVImmunicNASDAQ: IMUXKerostxNASDAQ: KROSMereo BioPharma GroupNASDAQ: MREOProtalixNYSE: PLXSoligenixNASDAQ: SNGXSilverback Therapeuticsacq. by ARS Pharmaceuticals
Portfolio news
latest coverage across their companiesProtalix · tickerreport.com · Aug 20, 2026
LogicBio · themarketsdaily.com · Aug 20, 2026
ProQR · investing.com · Aug 20, 2026
Immunic · themarketsdaily.com · Aug 19, 2026
Abcuro · clinicaltrialsarena.com · Aug 19, 2026
Urogen · investing.com · Aug 19, 2026
Adicet Bio · stocktitan.net · Aug 14, 2026
Mereo BioPharma Group · tradingview.com · Aug 11, 2026
Frequently asked questions
- How many investments has Pontifax Venture Capital made?
- Pontifax Venture Capital has 70 tracked investments, 10 of which have exited, including 1 dated in the last 24 months.
- What stage does Pontifax Venture Capital invest at?
- Pontifax Venture Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Pontifax Venture Capital's typical check size?
- Pontifax Venture Capital typically writes checks of $6.3M – $128M.
- What sectors does Pontifax Venture Capital focus on?
- Pontifax Venture Capital focuses on Biotech, Deep Tech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Pontifax Venture Capital located?
- Pontifax Venture Capital is headquartered in Herzeliya, IL.
- Does Pontifax Venture Capital lead rounds?
- Pontifax Venture Capital typically participates in rounds rather than leading them.
- Who does Pontifax Venture Capital co-invest with?
- Pontifax Venture Capital most often shares deals with OrbiMed, RA Capital, Kurma Partners, among 65 tracked co-investors.
Images
Co-investors · 15
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Andera Partners is an asset management firm specializing in private equity that partners with companies and their management to support sustainable growth. It has backed 377 companies over more than 20 years.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
HealthCap is a life science venture capital investor and company creator that backs innovative healthcare ideas, people, and companies aiming to impact healthcare and society.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Domain Associates is a venture capital firm founded in 1985 that invests in life sciences companies. The firm operates as a limited liability company.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.
▶3 more co-investors
Firms observed investing alongside Pontifax Venture Capital, from public investor directories. Shared companies are the overlap with Pontifax Venture Capital's recorded portfolio.
Similar investors
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.